55mOpinion
Hosted on MSN2 Investment Management Stocks to Buy Amid Industry HeadwindsThe Zacks Investment Management industry continues to bear the brunt of a constant shift toward passive investing. As fees ...
57m
Hosted on MSNThis Top Retail and Wholesale Stock is a #1 (Strong Buy): Why It Should Be on Your RadarIt doesn't matter if you're a growth, value, income, or momentum-focused investor -- building a successful investment portfolio takes skill, research, and a little bit of luck. How do you find the ...
Abercrombie expects full-year earnings to be $10.40 to $11.40 per share. Abercrombie shares have declined 36% since the beginning of the year. The stock has fallen 30% in the last 12 months.
EyePoint Pharmaceuticals (EYPT) on Wednesday reported a loss of $41.4 million in its fourth quarter. On a per-share basis, the ...
The Pasadena, California-based company said it had profit of 34 cents per share. Earnings, adjusted for one-time gains and costs, came to 87 cents per share. The results missed Wall Street ...
On a per-share basis, the Brookfield, Wisconsin-based company said it had profit of 35 cents. Earnings, adjusted for one-time gains and costs, were 40 cents per share. The results beat Wall Street ...
NEW YORK (AP) — NEW YORK (AP) — Riskified Ltd. (RSKD) on Wednesday reported a loss of $4.1 million in its fourth quarter. On a per-share basis, the New York-based company said it had a loss of 2 cents ...
Vistra Corp. (VST) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...
The Redwood City, California-based company said it had a loss of $1.41 per share. Losses, adjusted for one-time gains and costs, came to 64 cents per share. The results surpassed Wall Street ...
For the current quarter ending in April, Box expects its per-share earnings to range from 25 cents to 26 cents. The company said it expects revenue in the range of $274 million to $275 million for the ...
The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 55 cents per share. The drug developer posted revenue of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results